Overview

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Tofacitinib